Search - tctmd.com

Displaying 141 - 160 of 189

Sort: Relevancy | Date

News Industry News

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

May 23, 2014

News Industry News

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

May 21, 2014

News Industry News

Experts in Interventional Cardiology to Highlight CorPath Robotic Angioplasty at SCAI 2014 Scientific Sessions

May 21, 2014

News Industry News

Elixir Medical Corporation to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

May 14, 2014

News Industry News

Biscayne Pharmaceuticals' GHRH Technology Featured In Presentations At International Society For Heart Research Meeting

May 14, 2014

News Industry News

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

May 13, 2014

News Industry News

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

May 07, 2014

News Industry News

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

May 01, 2014

News Industry News

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

March 27, 2014

News Industry News

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

March 24, 2014

News Industry News

ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease

January 13, 2014

News Industry News

Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System

September 03, 2013

News Industry News

Medtronic Submits First 'PMA' Module for IN.PACT Admiral Drug-Eluting Balloon

August 15, 2013

News Industry News

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

June 11, 2013

News Industry News

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

June 04, 2013

News Industry News

Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States

May 08, 2013

News Industry News

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

May 01, 2013

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

October 24, 2012

Advertisement

Elixir Medical Announces Outstanding Long-term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-approved Novolimus Eluting Coronary Intervention Systems

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Experts in Interventional Cardiology to Highlight CorPath Robotic Angioplasty at SCAI 2014 Scientific Sessions

Elixir Medical Corporation to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Biscayne Pharmaceuticals' GHRH Technology Featured In Presentations At International Society For Heart Research Meeting

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

The Medicines Company and Alnylam Announce Presentation of New Pre-Clinical Data on PCSK9 at Arteriosclerosis, Thrombosis and Vascular Biology 2014 Scientific Sessions

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease

Medtronic Presents Final Three-Year Data From Symplicity HTN-1 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System

Medtronic Submits First 'PMA' Module for IN.PACT Admiral Drug-Eluting Balloon

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold

St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood Pressure

Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne® Nx Novolimus Eluting Coronary Stent System in the United States

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content